Evidence map›Paper›PMID 42003882›Full record

ArticleMolecular therapy. Nucleic acids2026

Characterization of RNA using mass photometry: Method and technical perspectives.

Lauren F Barnes, Brenda Watt, Salma Jalal, Gogulan Karunanithy, Matthew J Ranaghan, Josephine Rood, Hanliu L Wang

Abstract read
In one paragraph

Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lauren F BarnesBio Therapeutics Pharmaceutical Sciences, Pfizer Inc, Chesterfield, MO 63017, USA.
Brenda WattRefeyn, Inc., Waltham, MA 02451, USA.
Salma JalalRefeyn Ltd., Oxford OX4 6FF, UK.
Gogulan KarunanithyRefeyn Ltd., Oxford OX4 6FF, UK.
Matthew J RanaghanRefeyn, Inc., Waltham, MA 02451, USA.
Josephine RoodBio Therapeutics Pharmaceutical Sciences, Pfizer Inc, Chesterfield, MO 63017, USA.
Hanliu L WangBio Therapeutics Pharmaceutical Sciences, Pfizer Inc, Chesterfield, MO 63017, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Developing analytical methods for RNA-based products, such as mRNA vaccines, requires tools that support release testing, stability assessment, and characterization. Mass photometry (MP) is a label-free, single-molecule technique increasingly applied to biotherapeutics and vaccines. Here, we outline best practices and technical considerations for using MP to analyze vaccine mRNA constructs and other RNA samples. With appropriate calibration, MP provides mRNA molecular weight and quantifies heterogeneous species, including those difficult to resolve using traditional techniques. We systematically evaluated experimental parameters influencing RNA measurements, including surface chemistry and buffer composition, and show that cationic-coated sample carriers and salt-containing buffers are essential for reproducible detection and mass resolution. Low-mass species were assessed using multiple mRNA constructs, kinetic analysis, and buffer controls to distinguish genuine sample heterogeneity from method artifacts. We further examined the effects of ionic additives on oligomeric species. MP results were compared with charge detection mass spectrometry and fragment analyzer measurements, showing good agreement when accounting for differences in measurement principles. Overall, MP provides a rapid, low-sample consumption, and information-rich approach for mRNA characterization and quality assessment, either as a standalone method or as an orthogonal complement to established RNA analytical techniques.

Indexed as

mass photometrymRNA characterizationmRNA vaccineMT: RNA/DNA editingRNAsample characterizationvaccine and therapeutics development

Identifiers

PMID42003882
PMCPMC13091337

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.